News
Privately-held Spanish CNS specialist Minoryx Therapeutics and Germany’s Neuraxpharm Group today announce that the marketing authorization application (MAA) for Minoryx’ lead candidate Nezglyal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback